*EISAI-E7080-G000-205 Ph1b

Study Sponsor: Eisai

Study Title

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Medicine or Vaccine (generic name)

lenvatinib

Sponsor Identification Number

E7080-G000-205 Ph1b

Trial Registry Identification Number(#'s)

NCT01136733
EU CTR 2010-019484-10

Medical Condition

Metastatic Renal Cell Carcinoma

Phase

Phase 1

Link to study details on the Eisai Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT01136733

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019484-10

Datasets and Documents Available for this Study

Additional information about the data and documents available for this study

No restrictions. Note: The Protocol and Statistical Analysis Plan are part of the phase 2 study documents.

Date Added to this Site

November 2017